ArticlePharmacoEconomics2022
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Article in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers.Frontiers in pharmacology · 2023Pooled it
- Price trend, clinical benefit and within-class competition of drugs for metastatic Non-small cell lung cancer in China: a retrospective cohort study.The Lancet regional health. Western Pacific · 2026Article
- Clinical value and cost-effectiveness analysis of conditionally approved anticancer drugs in China from 2015 to 2023.Translational cancer research · 2026Article
- A comparative analysis of health technology assessment decision-making for cancer drugs in Germany and England.Frontiers in public health · 2026Article
- Cost-effectiveness of first-line aumolertinib versus osimertinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer in China.Frontiers in public health · 2026Article
- Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China.Frontiers in pharmacology · 2026Article
- Hospital spending for cancers in Hunan, China during 2017 and 2019.BMC public health · 2025Article
- Characteristics of indications, clinical trial evidence, clinical benefits and the costs of price-negotiated multi-indication drugs for solid tumours in China.Journal of global health · 2025Article
- Comparative Assessment of Pivotal Trials Supporting the Indication Approvals of Innovative and Modified New Anticancer Drugs in China, 2016-2022.Health data science · 2025Article
- Pricing, price revision, and clinical value of anticancer drugs in Japan: a retrospective observational study.Frontiers in pharmacology · 2025Article
- Quantitative evaluation of dual-channel drug supply policy on nationally negotiated anti-tumor drugs in Xuzhou: based on interrupted time series analysis.Frontiers in pharmacology · 2025Article
- Medicine availability and affordability for paediatric cancers, China.Bulletin of the World Health Organization · 2025Article
- Impact of competition on reimbursement decisions for cancer drugs in China: an observational study.The Lancet regional health. Western Pacific · 2024Article
- List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study.The Lancet regional health. Western Pacific · 2024Article
- Immune checkpoint inhibitorsTherapeutic advances in gastroenterology · 2024Review
- Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis.Frontiers in pharmacology · 2024Article
- Price negotiation and pricing of anticancer drugs in China: An observational study.PLoS medicine · 2024Observational
- The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China.Journal of global health · 2023Article
- Article
- National value-based pricing negotiation for oncology drugs - lessons from China.Nature reviews. Clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh prices of anticancer medicines have increased the economic burden for both patients and health insurance systems. Since 2017, China has implemented national price negotiations for medicines, relying on evidence from health technology assessments. We aim to assess the relation between negotiated price and value of anticancer medicines listed in China's National Reimbursement Drug List (NRDL).
methodsFor all price-negotiated anticancer medicines and corresponding indications listed in the latest NRDL between 2017 and 2020, we collected their clinical outcomes data, including overall survival (OS) and progression-free survival (PFS), in supporting trials. Pearson correlation coefficient was calculated to estimate the association between the daily cost and clinical benefit of each indication.
resultsIn total, 75 indications of 46 branded anticancer medicines were included for analysis. The median daily costs for the anticancer therapies that had gone through negotiation in 2017-2020 were US$87.6, US$71.8, US$58.9, and US$39.7, respectively. For indications supported by randomized trials, no correlation between daily costs and OS and PFS benefit of the price-negotiated cancer therapies was observed (N = 41, r = -0.05, and N = 49, r = 0.04, respectively). For cancer indications newly listed in NRDL in 2020, the association between their daily cost and OS benefit was -0.78 (N = 4, p = 0.221) and 0.01 (N = 8, p = 0.986) before and after the price negotiation.
conclusionThough the negotiation policy decreased prices of anticancer medicines in China, no statistically significant correlation was observed between their daily costs and clinical benefits. A more transparent and credible pricing approach needs to be established to promote value-based anticancer medicines and healthcare system efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.